Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China

Yu Chen, Peng Ye, Chongwu Ren, Pengfei Ren, Zheng Ma, Lin Zhang, Wenliang Zhou, Changjie Jiang, Yu Chen, Peng Ye, Chongwu Ren, Pengfei Ren, Zheng Ma, Lin Zhang, Wenliang Zhou, Changjie Jiang

Abstract

To evaluate the pharmacoeconomics of three therapeutic schemes in treating anti-tuberluosis therapy -induced liver injury (anti-TB DILI).

Methods: In the construction of a decision tree model, the efficacy and safety parameters came from the results of the randomized, controlled trial conducted here, the effect parameters were derived from expert advice, and the cost parameters, such as usage specification, number, and unit price, came from literature, expert advice, and so on.

Results: The cost-effectiveness analysis (CEA) based on the effect degrees showed that bicyclol had the best effect (4.63562). The incremental cost-effectiveness ratio (ICER) (206.03270) of bicyclol was the lowest. The cost-effectiveness ratio of silibinin was the lowest (68.59987). The CEA based on the complete normalization rate showed that bicyclol had the highest complete normalization rate (83.562%), the lowest cost-effectiveness ratio (4.63627), and the smallest ICER (4.63504). Sensitivity analyses proved the robustness of the results.

Conclusions: Bicyclol is the most cost-effective therapy and the preferred choice for treating anti-TB DILI.

Keywords: Anti-TB DILI; Cost-effectiveness analysis; Decision trees analysis; Pharmacoeconomics; Prospective.

Conflict of interest statement

Conflicts of interest: Authors state no conflict of interest.

Figures

Figure 1
Figure 1
Decision tree model structure The decision node is represented with “□” and it is the starting point of the decision problem. The state point is represented with “O,” indicating the status that the scheme has met with. The lines drawn from the state point indicate a variety of possible states that may occur; next to them, all status contents are marked, and the degree of possibility for development is expressed by probability. The terminal point of decision is expressed by “Δ,” next to which the assigned value of each effect degree is marked.
Figure 2
Figure 2
Cost-effectiveness frontier

References

    1. Glaziou P., Floyd K., Weil D., Raviglione M.. TB deaths rank alongside HIV deaths as top infectious killer. Int J. Tuberc Lung Dis. 2016;2:143–144. doi: 10.5588/ijtld.15.0985.
    1. The technical guidance group of the fifth national tuberculosis epidemiological random sampling survey, the office of the fifth national tuberculosis epidemiological random sampling survey, The report of the fifth national tuberculosis epidemiological random sampling survey in 2010. Chin J. Antituberculosis prevention. 2012;8:485–508.
    1. Donglou X., Yu M., Lizhen Z. Diagnostic manual for adverse reactions of antituberculosis drugs. 1st. People’s Medical Publishing House; Beijing: 2009.
    1. Chengwei C.. Pathogenesis and treatment strategies of drug-induced liver injury. Zhonghua Jie He He Hu Xi Za Zhi. 2013;10:726–728. doi: 10.3760/cma.j.issn.1001-0939.2013.10.004.
    1. Heping X., Jin G.. Clinical characteristics of antituberculosis drug-induced liver injury. Chin J. tuberculosis prevention. 2013;7:485–487.
    1. Chinese journal of tuberculosis and respiratory, editorial board, tuberculosis branch of the Chinese Medical Association, Expert advice on diagnosis and treatment of the antituberculosis therapy Induced Liver Injury. Chin J. Tuberculosis and Respiratory Diseases. 2013;10:732–736. doi: 10.3760/cma.j.issn.1001-0939.2013.10.007.
    1. Interpretation of guidelines for diagnosis and treatment of drug induced liver injury. 1st. Shanghai Science and Technology Press; 2015. The Drug-Induced Liver Disease Group, Branch Association of Hepatology, Chinese Medical Association; p. Shanghai.
    1. Kermode M.. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int. 2004;1:95–103.
    1. Evaluation guidelines of Chinese pharmacoeconomics by the research group, a guide for China’s pharmaceutical economics evaluation: 2011 edition. Chin J. Pharmaceutical economics. 2011;3:6. doi: 10.3969/j.issn.1673-5846.2011.03.001.
    1. Aihua W., Hongbo T., Xinlei L., Ning Z., Xin F.. Evaluation of pharmacoeconomics of oral anti-inflammatory hepatoprotective drugs in the treatment of drug-induced liver injury. Chin J. Gastroenterol Hepatol. 2015;10:1232–1237. doi: 10.3969/j.issn.1006-5709.2015.10.021.
    1. Guangyu H., Yuming W.. Pharmacoeconomics profiles of four hepatoprotective drugs used for the treatment of drug-induced liver injury. Chin J. Hepatol. 2014;10:763–768. doi: 10.3760/cma.j.issn.1007-3418.2014.10.010.
    1. Martello JL, Pummer TL, Krenzelok EP. Cost minimization analysis comparing enteral N-acetylcysteine to intravenous acetylcysteine in the management of acute acetaminophen toxicity. Clin Toxicol (Phila) 2010;1:79–83. doi: 10.3109/15563650903409799.
    1. Senarathna SM, Sri Ranganathan S, Buckley N, Fernandopulle R. A cost effectiveness analysis of the preferred antidotes for acute paracetamol poisoning patients in Sri Lanka. BMC Clin Pharmacol. 2012;12:6. doi: 10.1186/1472-6904-12-6.
    1. Ministry of Health of the People’s Republic of China, Diagnostic Criteria for Pulmonary Tuberculosis. People’s Republic of China sanitary industry standard: WS 288-2008
    1. Danan G, Benichou C. Causality assessment of adverse reactions to drugs I, A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.
    1. Xiangnan G., Sheng H., Lu X., Luwen S.. The primary exploration of the economic evaluation method for essential drugs in China. Chin Pharmaceutical J. 2011;12:963–966.
    1. Xiaodong K.. Pharmacoeconomics: Concepts, Methods and applications. Foreign medical sciences Pharmaceutical fascicule. 1994;1:18. doi: 10.13220/j.cnki,jipr.1994.01.003.
    1. Metushi IG., Uetrecht J.. Isoniazid-induced liver injury and immune response in mice. J Immunotoxicol. 2014;4:383–392. doi: 10.3109/1547691X.2013.860644.
    1. Metushi IG., Cai P., Zhu X., Nakagawa T., Uetrecht JP.. A Fresh Look at the Mechanism of Isoniazid-Induced Hepatotoxicity. Clin Pharmacol Ther. 2011;6:911–914. doi: 10.1038/clpt.2010.355.
    1. Chengwei C. Drug and toxic liver disease. 2nd. Shanghai Science and Technology Press; Shanghai: 2013.
    1. Saukkonen JJ., Cohn DL., Jasmer RM., Schenker S., Jereb JA., Nolan CM.. et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med. 2006;174:935–952. doi: 10.1164/rccm.200510-1666ST.
    1. Yuecheng Y., Yimin M., Chengwei C., Jinjun C., Jun C., Wenming C.. et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221–241. doi: 10.1007/s12072-017-9793-2.
    1. Shen C., Cheng X., Li D., Meng Q.. Investigation of rifampicin-induced hepatotoxicity in rat hepatocytes maintained in gel entrapment culture. Cell Biol Toxicol. 2009;3:265–274. doi: 10.1007/s10565-008-9076-8.
    1. Shen C, Zhang H, Zhang G, Meng Q. Isoniazid-induced hepatotoxicity in rat hepatocytes of gel entrapment culture. Toxicol Lett. 2006;1:66–74. doi: 10.1016/j.toxlet.2006.08.010.
    1. Miyazawa N, Takahashi H, Yoshiike Y, Ogura T, Watanuki Y, Sato M. et al. Effect of glycyrrhizin on anti-tuberculosis drug-induced hepatitis. Kekkaku. 2003;1:15–19.
    1. E-Gazayerly ON, Makhlouf AI, Soelm AM, Mohmoud MA. Antioxidant and hepatoprotective effects of silymarin phytosomes compared to milk thistle extract in CCl4 induced hepatotoxicity in rats. J Microencapsul. 2014;1:23–30. doi: 10.3109/02652048.2013.805836.
    1. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage. Arch Pharm Res. 2011;5:767–774. doi: 10.1007/s12272-011-0510-8.
    1. Li J., Lin WF, Pan YY, Zhu XY. Protective effect of silibinin on liver injury induced by antituberculosis drugs. Zhonghua Gan Zang Bing Za Zhi. 2010;5:385–386. doi: 10.3760/cma.j.issn.1007-3418.2010.05.019.
    1. Zhao J., Chen H., Li Y.. Protective effect of bicyclol on acute alcohol-induced liver injury in mice. European Journal of Pharmacology. 2008(1–3):322–331. doi: 10.1016/j.ejphar.2008.02.059.
    1. Wang HP., Li Y.. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. European Journal of Pharmacology. 2006(1–3):194–201. doi: 10.1016/j.2005.12.080.
    1. Liu G.T., Li Y., Wei HL., Zhang H., Xu JY., Yu LH.. Mechanism of protective action of bicyclol against CCl4-induced liver injury in mice. Liver International. 2005;25:872–879. doi: 10.1111/j.1478-3231.2005.01103.x.
    1. Chu N.H., Li L., Zhang X., Gu J., Du YD., Cai C.. et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J. Tuberc Lung Dis. 2015;4:475–480. doi: 10.5588/ijtld.14.0579.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa